Caretha Creasy and Kevin W. Kuntz have developed chemicals that block the function of the hyperactive mutated EZH2 protein, without blocking its normal counterpart. The drugs haven’t been tested in actual cancer patients yet. However, they correct the abnormal pattern of epigenetic modifications and reactivate genes which have been inappropriately silenced in human lymphoma cells grown in the laboratory. Most importantly, the drugs also slow the growth of the lymphoma cells.
